Could comorbid insomnia in Alzheimer’s disease increase overall health costs?

Written by Darcy Hodge, Editor

Comorbid Insomnia AD Costs

Researchers from Merck & Co. (NJ, USA) and IBM Watson Health (MA, USA) have published findings in the Journal of Alzheimer’s Disease to highlight that comorbid insomnia in Alzheimer’s disease (AD) was more likely to lead to a greater cost burden compared to patients who did not have insomnia. At an estimate, 5.8 million Americans aged 65 or over are currently diagnosed with AD, and this is expected to double by 2050. In 2019, the costs of caring for individuals with AD – encompassing both immediate healthcare and long-term care – were approximately USD$290 billion. Therefore, highlighting the financial significance of AD.  In the disease, sleep disorders are...

To view this content, please register now for access

It's completely free